基于磁共振成像与前列腺特异性抗原密度的风险分层可减少低危前列腺癌主动监测中不必要的随访活检
研究纳入210例Gleason评分3+3前列腺癌且接受主动监测的男性,行首次磁共振成像(MRI)及必要时靶向活检。MRI±靶向活检检出Gleason评分升级者占24%(51/210),A、B、C三组分别为23%、23%和27%。PI-RADS评分1-3且PSA-D<0.15 ng/mL²者未见Gleason评分升级,基于PI-RADS与PSA-D的风险分层可能减少不必要的随访活检。
要点
- 210例主动监测男性中,MRI阳性134/210(64%),MRI-靶向活检检出Gleason评分升级51/210(24%)。
- A、B、C三组Gleason评分升级比例分别为23%(22/97)、23%(9/39)、27%(20/74)。
- PI-RADS 1-3且PSA-D<0.15 ng/mL²者(n=15)未检出Gleason评分升级。
核心结论
- 至少五分之一的Gleason评分3+3前列腺癌主动监测男性在基线、确认性或监测活检时基于首次MRI±靶向活检出现Gleason评分升级。
- PI-RADS评分1-3且PSA-D<0.15 ng/mL²的男性在主动监测各时间点MRI±靶向活检或TRUS-Bx均未出现Gleason评分升级,基于PI-RADS与PSA-D的风险分层可能减少不必要的随访活检。
研究设计与样本
- 研究纳入210例Gleason评分3+3前列腺癌且接受主动监测的男性,均接受首次MRI,若PI-RADS评分≥3则行MRI-TRUS融合靶向活检。
- MRI于诊断后3个月(A组,n=97)、确认性活检时(B组,n=39)或一次以上重复TRUS引导系统活检后的监测活检时(C组,n=74)进行。
- 主要结局为A、B、C组基于MRI±靶向活检的Gleason评分升级至≥3+4前列腺癌。
- 活检结局按总体PI-RADS评分和PSA-D分层,以识别可避免活检的亚组。
主要发现
- 210例中134例(64%)MRI阳性,51例(24%)基于MRI-靶向活检出现Gleason评分升级。
- 基于MRI-靶向活检的Gleason评分升级比例在A组为23%(22/97)、B组为23%(9/39)、C组为27%(20/74)。
- TRUS-Bx额外检出Gleason评分升级者占B组8%(3/39)、C组接受TRUS-Bx者6%(1/17)。
- PI-RADS评分3且PSA-D<0.15 ng/mL²者(n=15)MRI-靶向活检未检出Gleason评分升级。
- PI-RADS评分1-3且PSA-D<0.15 ng/mL²者(n=15)TRUS-Bx未检出Gleason评分升级。
临床怎么用
- 作者认为,基于PI-RADS与PSA-D的风险分层可能减少主动监测男性的不必要随访活检程序。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the value of risk-stratification based on magnetic resonance imaging (MRI) and prostate-specific antigen density (PSA-D) in reducing unnecessary biopsies without missing Gleason pattern 4 prostate cancer in men on active surveillance (AS). PATIENTS AND METHODS: In all, 210 men on AS with Gleason score 3 + 3 prostate cancer received a first MRI and if indicated [Prostate Imaging Reporting and Data System (PI-RADS) score ≥3] targeted biopsy (TBx) using MRI-transrectal ultrasonography (TRUS) fusion. The MRI was performed 3 months after diagnosis (group A: n = 97), at confirmatory biopsy (group B: n = 39) or at surveillance biopsy after one or more repeat TRUS-guided systematic biopsies (TRUS-Bx) (group C: n = 74). The primary outcome was upgrading to Gleason score ≥3 + 4 prostate cancer based on MRI ± TBx in groups A, B and C. Biopsy outcomes were stratified for the overall PI-RADS score and PSA-D to identify a subgroup of men in whom a biopsy could have been avoided as no Gleason score upgrading was detected. RESULTS: In all, 134/210 (64%) men had a positive MRI and 51/210 (24%) men had Gleason score upgrading based on MRI-TBx. The percentage of Gleason score upgrading based on MRI-TBx was 23% (22/97), 23% (9/39) and 27% (20/74) in respectively groups A, B and C. Additional Gleason score upgrading detected by TRUS-Bx occurred in 8% (3/39) of men in group B and 6% (1/17) of men who received TRUS-Bx in group C. No Gleason score upgrading was detected by MRI-TBx in men with a PI-RADS score of 3 and a PSA-D of <0.15 ng/mL2 (n = 15), nor by TRUS-Bx in men with a PI-RADS score of 1-3 and a PSA-D of <0.15 ng/mL2 (n = 15). CONCLUSION: At least one out of five men on AS with Gleason score 3 + 3 prostate cancer at diagnostic TRUS-Bx show Gleason score upgrading based on first MRI ± TBx at baseline, confirmatory or surveillance biopsy. Men with a PI-RADS score of 1-3 and PSA-D of <0.15 ng/mL2 did not show Gleason score upgrading at MRI ± TBx or TRUS-Bx at each time point of surveillance. Thus risk-stratification based on PI-RADS and PSA-D may reduce unnecessary follow-up biopsy procedures in men on AS.
引用
- Alberts AR, Roobol MJ, Drost FH, et al. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer. BJU Int. 2017. PMID: 28267899. doi:10.1111/bju.13836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。